Study Stopped
Low enrollment
Ataxia in Essential Tremor: Describing the Differences Between Disease Process and Treatment Effect
ATAX
1 other identifier
observational
6
1 country
2
Brief Summary
The proposed study aims to characterize ataxia occurring in essential tremor and essential tremor with DBS.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for all trials
Started Dec 2018
2 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
December 1, 2018
CompletedFirst Submitted
Initial submission to the registry
December 6, 2018
CompletedFirst Posted
Study publicly available on registry
December 10, 2018
CompletedPrimary Completion
Last participant's last visit for primary outcome
September 14, 2020
CompletedStudy Completion
Last participant's last visit for all outcomes
September 14, 2020
CompletedSeptember 17, 2020
September 1, 2020
1.8 years
December 6, 2018
September 15, 2020
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Ataxia Differences between DBS and no DBS
Compare the Scale of the Assessment and Rating of Ataxia (SARA) total score between DBS and no DBS participants with essential tremor. This 8-item scale rates gait (0-8 points), stance (0-6 points), sitting (0-4 points), speech disturbance (0-6 points), finger chase (0-4 points), nose-finger test (0-4 points), fast alternating hand movements (0-4 points), and heel-shin slide (0-4 points). Motor activists of the four extremities (items 5-8) assessments are performed bilaterally, mean values to obtain a total score. Cumulative score ranges from 0 (no ataxia) to 40 (most severe ataxia).
Visit 2 (after DBS has been turned off for 3-10 days)
Secondary Outcomes (1)
Balance Confidence
Visit 2 (after DBS has been turned off for 3-10 days)
Study Arms (4)
ET (DBS-, Ataxia+)
Essential Tremor without DBS with Ataxia on examination
ET (DBS-, Ataxia-)
Essential Tremor without DBS and without Ataxia on examination
ET (DBS+, Ataxia+)
Essential Tremor with DBS with Ataxia on examination
ET (DBS+, Ataxia-)
Essential Tremor with DBS without Ataxia
Interventions
No interventions - Observational study
Eligibility Criteria
Essential Tremor participants with and without ataxia
You may qualify if:
- Essential Tremor diagnosis at least 3 years duration
- Absence of other neurological signes (such as dystonia, ataxia, or Parkinsonism)
- Patients must be able to walk 2 minutes unassisted.
- Patients must be able to understand and consent to be in the study.
You may not qualify if:
- Patients who have had changes in DBS settings within the last 3 months.
- Patients who have had no initial improvement or response to DBS.
- ET medication changes in the last month.
- Actively abusing alcohol.
- A neurologic diagnosis other than ET that in the investigator's opinion could affect gait and/or balance.
- Atypical tremor disorder including by not limited to tremor due to multiple sclerosis, medication-induced tremor, Parkinson's disease, or parkinsonian syndrome.
- Dementia
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Oregon Health and Science Universitylead
- Portland VA Medical Centercollaborator
Study Sites (2)
Oregon Health & Science University
Portland, Oregon, 97201, United States
VA Portland Health Care System
Portland, Oregon, 97239, United States
Related Publications (4)
Ramirez-Zamora A, Boggs H, Pilitsis JG. Reduction in DBS frequency improves balance difficulties after thalamic DBS for essential tremor. J Neurol Sci. 2016 Aug 15;367:122-7. doi: 10.1016/j.jns.2016.06.001. Epub 2016 Jun 2.
PMID: 27423573BACKGROUNDNazzaro JM, Lyons KE, Pahwa R. Deep brain stimulation for essential tremor. Handb Clin Neurol. 2013;116:155-66. doi: 10.1016/B978-0-444-53497-2.00013-9.
PMID: 24112892RESULTKronenbuerger M, Konczak J, Ziegler W, Buderath P, Frank B, Coenen VA, Kiening K, Reinacher P, Noth J, Timmann D. Balance and motor speech impairment in essential tremor. Cerebellum. 2009 Sep;8(3):389-98. doi: 10.1007/s12311-009-0111-y. Epub 2009 May 19.
PMID: 19452239RESULTFasano A, Herzog J, Raethjen J, Rose FE, Muthuraman M, Volkmann J, Falk D, Elble R, Deuschl G. Gait ataxia in essential tremor is differentially modulated by thalamic stimulation. Brain. 2010 Dec;133(Pt 12):3635-48. doi: 10.1093/brain/awq267. Epub 2010 Oct 5.
PMID: 20926368RESULT
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Design
- Study Type
- observational
- Observational Model
- CASE CONTROL
- Time Perspective
- CROSS SECTIONAL
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Associate Professor
Study Record Dates
First Submitted
December 6, 2018
First Posted
December 10, 2018
Study Start
December 1, 2018
Primary Completion
September 14, 2020
Study Completion
September 14, 2020
Last Updated
September 17, 2020
Record last verified: 2020-09
Data Sharing
- IPD Sharing
- Will share
- Shared Documents
- STUDY PROTOCOL, ICF
- Time Frame
- Data will be available within 6 months of study completion.
- Access Criteria
- Data access requests will be reviewed by an external Independent Review Board. Requestors will be required to sign a data access agreement.
Post data entry and verification, data and specimens will be de-identified (no 18 HIPAA identifiers and age aggregated for those \> 89 years old) and transferred to the Neurological Disorder Repository (MIRB # 3129). This repository is maintained at the Portland VA Health Care System. Verification of the coded data set creation and the absence of the identifiers will be created and retained in the study files. The research coordinator will be responsible for the creation and verification process. The key to the code will be maintained by the study and will not be released to the repository. The recipient investigator must present the data use agreement, documentation of an Institutional Review Boar (IRB) approved protocol and Informed Conset Form (ICF) allowing the release of the identifiable specimens/data, or the release of coded specimens/data.